News
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
This version of our ongoing better buy series pits two development-stage biotechs, Bellicum Pharmaceuticals (NASDAQ: BLCM) and bluebird bio (NASDAQ: BLUE), against each other. The companies have....
This Drug Pricing Scheme Could Be Making Your Medicine More Expensive
Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers.....
This Drug Pricing Scheme Could Be Making Your Medicine More Expensive
Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers.....
Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today
Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biopharmaceutical company primarily focused on cancer and blood-based disorders, are rising in response to some surprising early stage....
Why DexCom Stock Is Getting Crushed Today
Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. This tumble stemmed from the....
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....
This Marijuana Stock May Already Be Running Out of Chances to Succeed
In case you haven't noticed, the marijuana industry is growing by leaps and bounds. According to cannabis research firm ArcView, the legal weed industry in North America is estimated to grow by....
5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more.Celgene's past success stemmed primarily from....
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE: JNJ) stock has largely tread water over the last few months. Wouldn't it be nice if the healthcare giant had a catalyst or....
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE: JNJ) stock has largely tread water over the last few months. Wouldn't it be nice if the healthcare giant had a catalyst or....
Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?
Historically, 99% of Alzheimer's disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer's disease drug,....
Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?
Historically, 99% of Alzheimer's disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer's disease drug,....
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Here's Why PTC Therapeutics, Inc. Is Slipping Today
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) have fallen 17.3% as of 11:53 a.m. EDT on Tuesday. Recently released briefing documents left investors even less hopeful an upcoming independent....
3 Biotech Stocks With Major Catalysts in October
Every month brings plenty of catalysts for several biotech stocks. October is no exception. There are quite a few regulatory decisions and clinical results expected to be announced next....
3 Biotech Stocks With Major Catalysts in October
Every month brings plenty of catalysts for several biotech stocks. October is no exception. There are quite a few regulatory decisions and clinical results expected to be announced next....
3 Reasons to Buy the Dip With Exelixis
In just two days, Exelixis (NASDAQ: EXEL) has lost over 15% of its market cap. The tumble for the once-hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink....